An Open-label Pilot Study of NicoBloc as a Novel Smoking Cessation Intervention.
An Open-label Pilot Study of NicoBloc as a Novel Smoking Cessation Intervention.
复制标题
NicoBloc 作为新型戒烟干预措施的开放标签试点研究。
DOI：
10.1097/adm.0000000000001157
复制
发表时间：
2023
影响因子：
5.5
通讯作者：
Cropsey,KarenL
中科院分区：
文献类型：
--
作者：
Chichester,KeithR;Sisson,MichelleL;Chana,SofiaMildrum;Wolford-Clevenger,Caitlin;Hugley,MickeahJ;Hawes,ElizabethS;Palenski,Paige;Nguyen,Angela;Dahne,Jennifer;Hendricks,PeterS;Cropsey,KarenL
一个社区样本的主要是黑人吸烟者（N= 45，66.7%的黑人）被随机接受尼古丁或尼古丁含片。两组都进行了为期4周的戒烟治疗，随后进行了2个月的独立使用，每月进行检查以评估药物依从性。干预持续了12周，研究结束了1个月的干预后随访访视（16周）。ResultsNicoBloc是可比的尼古丁含片在减少吸烟，可行性，症状的不良反应，并报告在第16周的可接受性。含片组的参与者在干预期间认可了更高的治疗满意度和更低的香烟依赖性。坚持NicoBloc是上级在整个study.ConclusionNicoBloc是可行的，可接受的社区吸烟者。NicoBloc是一种独特的非药物干预。未来的研究需要检查这种干预是否可能是最有效的亚群药理学方法是有限的，或与已建立的药理学方法，如尼古丁替代疗法相结合。
MethodsA community sample of predominately Black smokers (N= 45; 66.7% Black) were randomized to receive NicoBloc or nicotine lozenge. Both groups engaged in 4 weeks of smoking cessation therapy followed by 2 months of independent usage with monthly check-ins to assess medication adherence. The intervention lasted 12 weeks, and the study concluded with a 1-month postintervention follow-up visit (week 16).ResultsNicoBloc was comparable with nicotine lozenge in smoking reduction, feasibility, symptom adverse effects, and reported acceptability at week 16. Participants in the lozenge group endorsed higher treatment satisfaction ratings during the intervention and lower cigarette dependence. Adherence to NicoBloc was superior throughout the study.ConclusionNicoBloc was feasible and acceptable to community smokers. NicoBloc presents a unique, nonpharmacological intervention. Future research is needed to examine whether this intervention may be most effective in subpopulations where pharmacological approaches are restricted or in combination with established pharmacological methods such as nicotine replacement therapy.